|
1 ngwa (10 Vials)
| Ọnụọgụ: | |
|---|---|
▎ Nchọpụta GLP-3
Kedu ihe ndabere nyocha nke GLP-3?
Ibu ibu aghọwo otu n'ime ihe ịma aka ahụike ọha ama ama na ọha mmadụ nke oge a. Ọ nwere ike ibute ọtụtụ nsogbu ahụike dịka ụdị 2 metabolism metabolism, ọrịa obi, ọbara mgbali elu, dyslipidemia, na ọrịa imeju na-adịghị egbu egbu. Site na mmụba na-aga n'ihu na mmụba nke oke ibu, a na-enwewanye mkpa ngwa ngwa maka ọgwụgwọ ọhụrụ nke nwere ike ijikwa oke ahụ nke ọma ma melite ọnọdụ ahụike [1] . Ọ bụ ezie na ntinye aka n'ụdị ndụ, dị ka mmega ahụ na-abawanye na njikwa ihe oriri, bụ isi usoro maka ịchịkwa ibu, ọ na-esiri ọtụtụ ndị ọrịa buru oke ibu ike ịnọgide na-ebufu ibu ogologo oge.
GLP-3, dị ka agonist atọ na-anabata ihe, nwere ike ime ihe na glucagon-dị ka peptide-1 nnabata.
GLP-1R), onye na-anabata insulinotropic polypeptide na-anabata glucose (GIPR), yana onye na-anabata glucagon (GCGR). Usoro ihe omume nke ọtụtụ ndị na-anabata ya na-enye ya uru dị ukwuu n'ọhịa nke ibu ibu. E jiri ya tụnyere ọgwụ na-ebelata ibu nke na-eme naanị otu onye na-anabata ya, GLP-3 nwere ike ịchịkwa usoro metabolic nke anụ ahụ [1] . GLP-3 na-enweta oke ibu site na ịhazi ọtụtụ ndị na-anabata homonụ, ọ bụghị naanị na-egosi nrụpụta dị ịrịba ama kamakwa na-enwe mmetụta dị nro nke eriri afọ. Na mgbakwunye, dị ka agonist atọ na-anabata ihe, GLP-3 nwere mmetụta mbelata ịdị arọ dị ike karị yana ọnụ ọgụgụ dị ukwuu nke ndị ọdabara ma e jiri ya tụnyere ọgwụ ndị ọzọ na-ebelata ibu arọ.
Kedu ihe bụ GLP-3?
GLP-3 bụ glucagon na-eme ogologo oge dị ka peptide-1 (GLP-1) agonist nnabata. A na-emezi ya ma kwalite ya dabere na nhazi nke GLP-1 eke, ọ nwere ike jikọta ma rụọ ọrụ GLP-1 onye na-anabata ya, na-arụ ọrụ physiological dị ka nke GLP-1 eke, dị ka ịkwalite secretion insulin, igbochi glucagon secretion, na-egbu oge ịpụsị gastric, ibelata agụụ, wdg. Ọ nwere nnukwu ngwa ngwa atụmanya nke metabolism.
Kedu ihe bụ usoro nke GLP-3?
Usoro nke GLP-3 na-esi na mmetụta agonistic na ọtụtụ ndị na-anabata ya. Nke mbụ, mmetụta ya na-akpata ya na onye na-anabata glucagon-dị ka peptide-1 (GLP-1R) nwere ike ime ka mmepụta insulin dịkwuo elu, na-egbochi glucagon secretion, na-ebelata ọkwa glucose n'ọbara, ma n'otu oge ahụ na-egbu oge nkwụsị nke gastric, na-abawanye satiety, ma belata oriri [2] . Nke abuo, mmetụta ya na-akpata ya na onye na-anabata insulinotropic polypeptide (GIPR) na-adabere na glucose nwere ike ịkwalite mmepụta insulin, kwalite ojiji glucose, ma na-emetụta abụba abụba, na-egbochi lipolysis na ịkwalite njikọ abụba [2] . Ọzọkwa, mmetụta agonist nke GLP-3 na onye na-anabata glucagon (GCGR) na-akwalitekarị glycogenolysis na gluconeogenesis na imeju, na-abawanye ọkwa glucose ọbara. Otú ọ dị, n'okpuru ọrụ GLP-3, mmetụta a na-ebuli glucose na-ebelata site na mmetụta nke abụọ ndị ọzọ na-anabata ya, na-akwalite lipolysis na ibelata mkpokọta abụba [2] . Ụdị omume nke ọtụtụ ebumnuche nwere ike ịdị irè karịa n'ịgwọ oke ibu karịa otu agonists nnabata.
Site n'otu oge na-eme ka ndị nnata atọ a rụọ ọrụ, GLP-3 nwere ike inwe mmetụta dị iche iche nke usoro metabolic ma mepụta mmetụta ọgwụgwọ na oke ibu na ọrịa ndị metụtara ya. N'ihe banyere ịhazi ọkwa glucose ọbara, ebe ọ bụ na ịgbalite GLP-1R na GIPR na-akwalite secretion insulin ma na-egbochi glucagon secretion, na ntinye nke GCGR na-emebi site na mmetụta nke abụọ ndị ọzọ na-anabata ya, GLP-3 nwere ike ịchịkwa ọkwa glucose ọbara nke ọma, nke dị oke mkpa maka ọgwụgwọ ụdị 22 metabolism . N'ihe banyere ibelata mkpokọta abụba, ịgbalite GCGR na-akwalite lipolysis ma na-ebelata mkpokọta abụba, ebe ịgbalite GLP-1R na-abawanye satiety ma belata oriri nri, na-ebelata njikọ abụba [1] . Na mgbakwunye, GLP-3 nwekwara mmetụta dị mma na ọrịa imeju na-adịghị egbu egbu. Ọ nwere ike ibelata abụba dị n'imeju ma melite ọrụ imeju.
HbA1c, arọ ahụ, ọbara mgbali, na lipids Data bụ ụzọ kacha nta-squares (ya na mpe mpe mpe mpe mpe mpe mpe mpe mpe mpe mpe mpe mpe mpe mperi na-egosi SE) site na nhazi nyocha nrụpụta ọrụ, ọ gwụla ma akọwapụtaghị ya.
Isi mmalite: PubMed [4]
Kedu akụkụ GLP-3 na-egosi mmetụta ya?
GLP-3 na-egosipụta mmetụta dị ukwuu n'ọtụtụ akụkụ
Mmetụta mbelata ibu dị mkpa: GLP-3 egosipụtala mmetụta mbelata oke ibu n'ọtụtụ nnwale ụlọ ọgwụ. Dịka ọmụmaatụ, n'ime ọmụmụ ụlọ ọgwụ metụtara ndị okenye 338 (Jastreboff AMM, 2023), ndị ọrịa a na-agwọ na GLP-3 dị iche iche nwere nnukwu ibu ibu na izu 48. N'ime ha, ndị ọrịa nọ na 12mg dose otu tụfuru 24.2% nke ịdị arọ ahụ ha, na ọnụ ọgụgụ dị elu nke ndị ọrịa na-enweta oke ibu na ogo dị iche iche. Dịka ọmụmaatụ, n'etiti ndị ọrịa na-anata 4mg, 8mg, na 12mg doses, 92%, 100%, na 100% nke ndị ọrịa, n'otu n'otu, tụfuru 5% ma ọ bụ karịa nke ahụ ha. N'ọmụmụ ihe ọzọ [3] , ule abụọ a na-achịkwa nke na-agụnye ndị ọrịa 353 nwere ụdị 2 nke metabolism na-egosi na e jiri ya tụnyere placebo, GLP-3 nwere ike ibelata arọ ahụ nke ndị ọrịa site na 11.89kg, ma belata haemoglobin glycated (HbA1C). Na mgbakwunye, na nnwale nke ndị okenye nwere oke ibu na-enweghị metabolism, GLP-3 kpatara mbelata ịdị arọ 24.2% na ndị ọrịa, na 83% nke ndị ọrịa tụfuru 15% ma ọ bụ karịa nke ahụ ha na izu 48. Nsonaazụ ndị a na-egosi na GLP-3 nwere ikike dị ukwuu na mbelata ibu.
Ọgwụgwọ nke ụdị 2 metabolism metabolism: GLP-3 na-egosikwa ụfọdụ ike na ọgwụgwọ nke ụdị 2 metabolism. N'ime ule ụfọdụ ụlọ ọgwụ, GLP-3 egosila mbelata nke haemoglobin glycated (HbA1c) yana mbelata ibu nke dabere na dose. Dịka ọmụmaatụ, n'otu nnyocha, n'ime ndị ọrịa nwere ụdị 2 metabolism, GLP-3 gosipụtara mmetụta nchịkwa glucose ọbara dị ịrịba ama. E jiri ya tụnyere placebo, haemoglobin glycated belatara site na 1.64% [3] . Tụkwasị na nke a, n'ime usoro 2 na-enweghị usoro, nke kpuru ìsì, na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-arụ ọrụ na-ejikọta ya na ụdị 2 nke metabolism, mgbe ọ natachara ọgwụgwọ GLP-3, gosipụtara mbelata dị ukwuu na ọkwa hemoglobin glycated, na arọ ahụ ha na-ebelatakwa n'ụzọ dabere na dose [4] . Enwere ike ịsị na nke a bụ nsonaazụ zuru oke nke ọgwụ na GLP-1, GCGR, na GIPR, nke na-eme ka metabolism glucose dịkwuo elu na nguzozi ike.
Mmelite nke ihe ize ndụ nke obi: GLP-3 nwere ike ọ bụghị naanị ibelata ibu ahụ kamakwa melite ihe egwu obi, dị ka profaịlụ lipid serum na ọkwa hemoglobin glycated. Nke a na-egosi njikọ chiri anya pathophysiological n'etiti oke ibu na ọrịa obi, yana GLP-3 nwere ike melite ahụike obi nke ndị ọrịa buru ibu site na ọtụtụ ụzọ. Dịka ọmụmaatụ, ibelata ọkwa na-abụghị HDL-C, apoB, na LDLP nwere ike ibelata ihe ize ndụ nke atherosclerosis; Mbelata ọkwa hemoglobin glycated nwere ike imezi njikwa glucose ọbara n'ime ndị ọrịa nwere metabolism, si otú ahụ belata ihe ize ndụ nke nsogbu obi obi [3, 5, 6]..
Ọgwụgwọ nke ọrịa imeju abụba na-adịghị egbu egbu (NAFLD): GLP-3 bụ peptide nke na-anabata glucagon receptor (GCGR), glucose-based insulinotropic polypeptide receptor (GIPR), na glucagon-dị ka peptide-1 receptor (GLP-1R). Nnyocha egosiwo na GLP-3 nwere ikike ịgwọ ọrịa imeju abụba na-adịghị egbu egbu. N'ime otu ọmụmụ, a na-eduzi ule a na-achịkwaghị achịkwa, nke kpuru ìsì abụọ, ebe a na-achịkwa placebo maka izu 48 na ndị na-eso ya nwere ọrịa imeju abụba na-emetụta ọrịa metabolic na-ejikọta ya na abụba imeju nke ≥10%. Nsonaazụ gosiri na n'ime izu 24, nkezi mgbanwe mgbanwe na abụba imeju site na ntọala nke ndị sonyere na-eji usoro dị iche iche nke GLP-3 (1mg, 4mg, 8mg, na 12mg) bụ -42.9%, -57.0%, -81.4%, na -82.4%, n'otu n'otu, ebe nke ahụ nọ na placebo bụ + 7.3 % . Nke a na-egosi na GLP-3 nwere ike inwe mmetụta ọgwụgwọ dị ukwuu na ọrịa imeju na-adịghị egbu egbu.
Na mmechi, dị ka akwụkwọ akụkọ atọ agonist receptor, GLP-3 na-egosi nnukwu ikike na ọgwụgwọ oke ibu na ọrịa ndị metụtara ya. Ọ nwere ike ịhazi metabolism nke mmadụ site n'ọtụtụ akụkụ site na ịgbalite onye na-anabata glucagon, onye na-anabata insulinotropic polypeptide na-adabere na glucose, yana onye na-anabata glucagon dị ka peptide-1, na-eme ka njikwa glucose ọbara dị mma, na-ebelata ibu ahụ, na ịhazi metabolism lipid. Mpụta nke GLP-3 ewetala nhọrọ ọgwụgwọ ọhụrụ maka ndị ọrịa nwere oke ibu, ụdị 2 metabolism, wdg. Ọ na-atụ anya imebi njedebe nke ọgwụ agonist otu onye na-anabata ya, na-enye ngwa ọgụ dị ike maka idozi nsogbu na-arịwanye elu nke oke ibu na ọrịa metabolic, na-akwalite mmepe n'ihu mmepe nke ngalaba ahụike metụtara, meziwanye ndụ ndị ọrịa, ma belata ibu ahụike ọha.
Banyere Onye dere ya
Ihe niile a kpọtụrụ aha n'elu bụ Cocer Peptides na-enyocha, dezie ma chịkọta ya.
Onye ode akwụkwọ akụkọ sayensị
Rosenstock J bụ ọkà mmụta nwere mmetụta dị ukwuu na ngalaba ahụike, na-arụkọ ọrụ ọnụ na ụlọ ọrụ dịka Mahadum Texas Southwestern Medical Center na Mahadum Texas Dallas. Ọ na-eduzi nyocha na ụlọ ọrụ dịka Canadian VIGOR Center na Veloc Clin Res Ctr Med City.
Nchoputa ya gbasara endocrinology na metabolism, sistemu obi obi na akwara obi, pharmacology, na nnwale nnwale, na-elekwasị anya na metabolism, oke ibu, na ọgwụgwọ metụtara ya na mmepe ọgwụ. J Rosenstock enwetawo ihe ịga nke ọma dị ịrịba ama na nkà mmụta ọgwụ, n'ịbụ onye a na-akpọ onye nyocha nke ukwuu site na 2017 ruo 2024. Nke a na-eme ka mmetụta dị elu na nkwanye ùgwù dị ukwuu nke ọrụ ya pụta ìhè. Site na mmekorita ya na ụlọ ọrụ nyocha dị iche iche, ọ tụgharịrị nke ọma nchọpụta nchọpụta bụ isi n'ime ngwa ụlọ ọgwụ, na-erite uru ndị ọrịa nwere ọrịa metabolic na ọrịa obi na ịkwalite sayensị ahụike. A na-edepụta Rosenstock J n'akwụkwọ ntụaka [4].
